Replies to post #49 on Dov Pharmaceuticals fka DOVP

[Virgilio]

If someone is betting on indiplon royalties as a cash measure to solve ANY problem I believe IMO he is dead wrong!

I do agree that bicifadine still has lots of partnerships potentials. Also the OA PII should be over by now and results available soon.

I do share the same optimism about the two compounds (21,947 and 216,303). The Company received 35M upfront a while back ago and can now re-license those compounds for higher upfront payments and lower l.t. payments. I believe something similar happened to REGN with Sanofi and while anyone said REGN's drug was dead since Sanofi returned the rights, a little time later REGN was able to strike a lucrative partnership with another Company.

Time will tell, but cash might come now from:

1) Dov 21,947;
2) Dov 216,303;
3) Bicifadine for chronic and acute pain;
4) Bicifadine for OA indication or other indications related to the compound + ibuprofen;
5) Dov Diltiazem;
6) Dov 102,677.

I would be very surprised to see that they aren't able to raise 70M out of all these drugs.